

AD_____

Award Number: W81XWH-06-1-0448

TITLE: The Role of Constitutively Active Prolactin Receptors in the Natural History of Breast Cancer

PRINCIPAL INVESTIGATOR: Kuang-tzu Huang, MS

CONTRACTING ORGANIZATION: University of California at Riverside
Riverside, CA 92521

REPORT DATE: April 2007

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.

1. REPORT DATE (DD-MM-YYYY) 01-04-2007			2. REPORT TYPE Annual Summary		3. DATES COVERED (From - To) 01 Apr 06 – 31 Mar 07			
4. TITLE AND SUBTITLE The Role of Constitutively Active Prolactin Receptors in the Natural History of Breast Cancer					5a. CONTRACT NUMBER			
					5b. GRANT NUMBER W81XWH-06-1-0448			
					5c. PROGRAM ELEMENT NUMBER			
6. AUTHOR(S) Kuang-tzu Huang, MS					5d. PROJECT NUMBER			
E-Mail: khuan001@student.ucr.edu					5e. TASK NUMBER			
					5f. WORK UNIT NUMBER			
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of California at Riverside Riverside, CA 92521					8. PERFORMING ORGANIZATION REPORT NUMBER			
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012					10. SPONSOR/MONITOR'S ACRONYM(S)			
					11. SPONSOR/MONITOR'S REPORT NUMBER(S)			
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited								
13. SUPPLEMENTARY NOTES								
14. ABSTRACT: Prolactin receptor (PRLR) is a single transmembrane receptor that normally requires ligand-binding to trigger intracellular signaling. Several isoforms of the human PRLR have been identified, including a long form (LF) and two short forms (SF1a and SF1b). These isoforms share identical amino acid sequence in the extracellular domain, but altered cytoplasmic domain as a consequence of alternative splicing. The extracellular domain consists of two fibronectin-like subdomains, S1 and S2. Recently we have identified the existence of naturally-occurring S2 deleted (delta S2) variants in several human cancer cell lines. We also showed that these human delta S2 isoforms were constitutively dimerized in the absence of PRL. When overexpressed in breast cancer cells, the delta S2 LF increased cell proliferation. The aim of our proposed training grant was to analyze the effect of delta S2 PRLR in a stable transfection system. We found that one of the S2 deleted short isoforms, delta S2 SF1b, was able to inhibit cell growth and migration.								
15. SUBJECT TERMS constitutively active prolactin receptor; cell proliferation; cell migration; signaling								
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT UU	18. NUMBER OF PAGES 7	19a. NAME OF RESPONSIBLE PERSON USAMRMC			
a. REPORT U					b. ABSTRACT U		c. THIS PAGE U	

Table of Contents

	<u>Page</u>
Introduction.....	4
Body.....	4
Key Research Accomplishments.....	5
Reportable Outcomes.....	5
Conclusion.....	6
References.....	6

INTRODUCTION


Prolactin (PRL) is a hormone that stimulates mammary gland development and milk protein production. It has also been indicated as a contributing factor to the pathogenesis and progression of several types of cancers, including breast cancer. Recent studies suggest PRL be an autocrine growth factor in normal and cancerous breast tissues (1-4). PRL acts through dimerized single membrane-spanning receptors, PRL receptors (PRLRs). Conformational changes of the dimerized receptors trigger intracellular signals via Jak2-Stat5, ERK, PI3K, and a number of other pathways (5-10). Several PRLR isoforms have been identified, including a long form (LF) and two short forms (SF1a and SF1b) (11, 12). These isoforms are produced by alternative splicing, which generates transcripts different in length of their cytoplasmic termini. The N-terminal extracellular domain of PRLR, which is identical in primary sequence in all three isoforms, consists of two fibronectin-like subdomains, S1 and S2 (13, 14). Preliminary studies from our laboratory have identified the existence of naturally-occurring S2 deleted (Δ S2) isoforms in several human cancer cell lines. We have also shown that the deleted Δ S2 isoforms are constitutively dimerized and activated in the absence of PRL. The Δ S2 PRLR LF has a growth-promoting effect in T-47D human breast cancer cells in a transient transfection experiment. We therefore established stable cell lines expressing Δ S2 PRLR LF, SF1a or SF1b to assess the biological activity of these isoforms. In this report, we show that all three isoforms can produce intracellular signals and one particular isoform, Δ S2 SF1b, can inhibit growth and migration of a human cancer cell line.

BODY

The aim of first year's work was to establish all expression constructs and perform a number of proposed assays so that necessary adjustments could be made. The first step was to subclone the Δ S2 PRLR cDNA (LF, SF1a, or SF1b) to a pcDNA3.1(+) expression vector (Invitrogen, Carlsbad, CA). After the correct DNA sequence was confirmed, these plasmids were transfected individually into several human cancer cell lines, including a well differentiated breast cancer cell line T-47D, poorly differentiated MDA-MB-231, and PC-3, a prostate cancer cell line that was used in one of the PI's major projects. Western blot analysis showed the proteins were well expressed and migrated toward the expected sizes (not shown).

Next we examined if the Δ S2 PRLR isoforms were able to produce intracellular signals. PRLR short forms were considered dominant negatives when first discovered (11, 12). We have previously shown that the molecular mimic of phosphorylated PRL, S179D PRL, can trigger a prolonged signal from the short receptors through the ERK signaling pathway (15). Therefore ERK activation of the Δ S2 PRLR short forms as well as Δ S2 LF was tested by Western blotting. Results indicated that all three S2 deleted isoforms could signal in the absence of PRL. Examples of Δ S2 LF and SF1b are shown here.

Our preliminary data suggest in a transient transfection system, Δ S2 PRLR LF has a promoting effect on cancer cell growth, whereas Δ S2 SF1b marginally decreases cell number. This is an effect when low transfection efficiency in these cells is expected. We therefore established stable cell lines to improve gene



delivery, and long-term activation of Δ S2 PRLRs could also be monitored. After 2-3 weeks of antibiotic selection, isolated colonies were analyzed for protein expression by Western blotting. Selected Δ S2 PRLR expressing cells were used for proliferation assays including the colorimetric formazan reduction assay (16) and direct cell counting. Taking one of the short forms as an example, the results showed a significant decrease in cell growth in Δ S2 SF1b cells compared to vector controls.

PRL has been shown to be a chemoattractant by activating the Ras and Rac signaling cascade (17). However, little is known how different PRLR isoforms alter cell migration. Migratory capacity was conducted using the wound healing assay and Boyden chamber migration assay. In the wound healing assay, wounds were introduced with a sterile tip to a monolayer of confluent cells. The extent of wound closure was measured after 16 hours. In the Boyden chamber migration assay, single-cell suspension was placed at 10^5 cell per well in the upper permeable support (8.0 μ m, Costar, Acton, MA). Medium containing 10% fetal bovine serum was placed in the lower chamber as a chemoattractant. After 16 hours, cells were methanol-fixed, and those which had not migrated through the membrane were wiped off with a cotton swab. Cells that had migrated to the lower surface of the membrane were stained with 1% toluidine blue. As shown in the figure, Δ S2 SF1b cells (lower panels) exhibit decreased motility compared to vector controls (upper panels).


KEY RESEARCH ACCOMPLISHMENTS

- established Δ S2 PRLR expression plasmids
- established Δ S2 PRLR stable cell lines
- conducted a series of *in vitro* assays regarding cell proliferation and migration using the Δ S2 PRLR stable cell lines

REPORTABLE OUTCOMES

Data obtained during this training period was in part presented in a poster session in the American Society for Cell Biology annual meeting. Two manuscripts were prepared for submission.

1. Huang KT and Walker AM. (2006) A naturally occurring, inducible, constitutively active isoform of the human prolactin receptor Δ S2 SF1b, reduces proliferation and migration in human prostate cancer cells. The American Society for Cell Biology 46th Annual Meeting, p66. Manuscript in preparation.
2. Tan D, Huang KT, Ueda E and Walker AM. (2007) S2 deletion variants of human PRL receptors demonstrate that extracellular domain conformation can alter conformation of the intracellular signaling domain, submitted.



CONCLUSION

From our preliminary results described above, one can conclude that the short receptor Δ S2 SF1b, inhibits cancer cell growth and migration. One can also expect a growth promoting effect from the Δ S2 LF. However, the level of endogenous full-length PRLR in the cells should also be considered. Several studies, including some from our lab, have noted heterodimerization of the long and short receptors can occur (18, 19). In addition, Gadd et al. report that artificially truncated PRLRs can also heterodimerize with endogenous receptors and alter PRL signaling (20). Therefore heterodimerization of the Δ S2 and endogenous PRLRs is possible. In cell lines with high PRLR expression, such as T-47D, heterodimerization is more likely to occur than those with very few normal receptors, such as MDA-MB-231. We would like to examine this possibility and have a better picture if interactions of different receptors may lead to different outcomes.

We have shown the inhibition of cell growth and migration in the Δ S2 SF1b stable cell line. However, we did not observe noticeable cell cycle defects or cell death. We suspected this was mainly because during the process of antibiotic selection, cells had been accustomed to the constitutive expression of Δ S2 SF1b. Changes in cell cycle might be compromised. To address this issue, an inducible expression system will be developed and used in future experiments, so that Δ S2 PRLR proteins can be expressed when needed.

REFERENCES

1. Ben-Jonathan, N., Liby, K., McFarland, M., and Zinger, M. Prolactin as an autocrine/paracrine growth factor in human cancer. *Trends Endocrinol Metab*, 13: 245-250, 2002.
2. Clevenger, C. V., Furth, P. A., Hankinson, S. E., and Schuler, L. A. The role of prolactin in mammary carcinoma. *Endocr Rev*, 24: 1-27, 2003.
3. Gutzman, J. H., Miller, K. K., and Schuler, L. A. Endogenous human prolactin and not exogenous human prolactin induces estrogen receptor alpha and prolactin receptor expression and increases estrogen responsiveness in breast cancer cells. *J Steroid Biochem Mol Biol*, 88: 69-77, 2004.
4. Vonderhaar, B. K. Prolactin involvement in breast cancer. *Endocr Relat Cancer*, 6: 389-404, 1999.
5. Goupille, O., Daniel, N., Bignon, C., Jolivet, G., and Djiane, J. Prolactin signal transduction to milk protein genes: carboxy-terminal part of the prolactin receptor and its tyrosine phosphorylation are not obligatory for JAK2 and STAT5 activation. *Mol Cell Endocrinol*, 127: 155-169, 1997.
6. Lebrun, J. J., Ali, S., Sofer, L., Ullrich, A., and Kelly, P. A. Prolactin-induced proliferation of Nb2 cells involves tyrosine phosphorylation of the prolactin receptor and its associated tyrosine kinase JAK2. *J Biol Chem*, 269: 14021-14026, 1994.
7. Das, R. and Vonderhaar, B. K. Activation of raf-1, MEK, and MAP kinase in prolactin responsive mammary cells. *Breast Cancer Res Treat*, 40: 141-149, 1996.
8. Das, R. and Vonderhaar, B. K. Involvement of SHC, GRB2, SOS and RAS in prolactin signal transduction in mammary epithelial cells. *Oncogene*, 13: 1139-1145, 1996.
9. Acosta, J. J., Munoz, R. M., Gonzalez, L., Subtil-Rodriguez, A., Dominguez-Caceres, M. A.,

Garcia-Martinez, J. M., Calcabrini, A., Lazaro-Trueba, I., and Martin-Perez, J. Src mediates prolactin-dependent proliferation of T47D and MCF7 cells via the activation of focal adhesion kinase/Erk1/2 and phosphatidylinositol 3-kinase pathways. *Mol Endocrinol*, *17*: 2268-2282, 2003.

10. Kline, J. B., Moore, D. J., and Clevenger, C. V. Activation and association of the Tec tyrosine kinase with the human prolactin receptor: mapping of a Tec/Vav1-receptor binding site. *Mol Endocrinol*, *15*: 832-841, 2001.

11. Trott, J. F., Hovey, R. C., Koduri, S., and Vonderhaar, B. K. Alternative splicing to exon 11 of human prolactin receptor gene results in multiple isoforms including a secreted prolactin-binding protein. *J Mol Endocrinol*, *30*: 31-47, 2003.

12. Hu, Z. Z., Meng, J., and Dufau, M. L. Isolation and characterization of two novel forms of the human prolactin receptor generated by alternative splicing of a newly identified exon 11. *J Biol Chem*, *276*: 41086-41094, 2001.

13. Bazan, J. F. Structural design and molecular evolution of a cytokine receptor superfamily. *Proc Natl Acad Sci U S A*, *87*: 6934-6938, 1990.

14. Kelly, P. A., Djiane, J., Postel-Vinay, M. C., and Edery, M. The prolactin/growth hormone receptor family. *Endocr Rev*, *12*: 235-251, 1991.

15. Wu, W., Ginsburg, E., Vonderhaar, B. K., and Walker, A. M. S179D prolactin increases vitamin D receptor and p21 through up-regulation of short 1b prolactin receptor in human prostate cancer cells. *Cancer Res*, *65*: 7509-7515, 2005.

16. Huang, K. T., Chen, Y. H., and Walker, A. M. Inaccuracies in MTS assays: major distorting effects of medium, serum albumin, and fatty acids. *Biotechniques*, *37*: 406, 408, 410-402, 2004.

17. Maus, M. V., Reilly, S. C., and Clevenger, C. V. Prolactin as a chemoattractant for human breast carcinoma. *Endocrinology*, *140*: 5447-5450, 1999.

18. Qazi, A. M., Tsai-Morris, C. H., and Dufau, M. L. Ligand-independent homo- and heterodimerization of human prolactin receptor variants: inhibitory action of the short forms by heterodimerization. *Mol Endocrinol*, *20*: 1912-1923, 2006.

19. Tan, D., Johnson, D. A., Wu, W., Zeng, L., Chen, Y. H., Chen, W. Y., Vonderhaar, B. K., and Walker, A. M. Unmodified prolactin (PRL) and S179D PRL-initiated bioluminescence resonance energy transfer between homo- and hetero-pairs of long and short human PRL receptors in living human cells. *Mol Endocrinol*, *19*: 1291-1303, 2005.

20. Gadd, S. L. and Clevenger, C. V. Ligand-independent dimerization of the human prolactin receptor isoforms: functional implications. *Mol Endocrinol*, *20*: 2734-2746, 2006.